Valneva eyes first place in chikungunya vaccine race
pharmaphorum
DECEMBER 5, 2022
Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.
Let's personalize your content